Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
inflammatory diseases
Biotech
Sanofi backs protein degrader after glimpse of clinical efficacy
In a small phase 1 trial, Kymera linked the IRAK4 candidate to improvements in symptoms, encouraging its partner Sanofi to take the program forward.
Nick Paul Taylor
Dec 14, 2022 7:00am
Paragon spinout Apogee makes debut with $169M
Dec 7, 2022 6:30am
Pfizer partners with Roivant for new inflammatory-focused Vant
Dec 1, 2022 10:30am
AbbVie links up with VC firm to map anti-inflammatory companies
Nov 28, 2022 7:30am
Amgen unveils new 245,000-square-foot R&D site in San Francisco
Oct 6, 2022 11:04am
Brickell Biotech paves fresh tracks with rebrand
Sep 7, 2022 12:03pm
